Analysis of Profitability Ratios
Quarterly Data
Beginner level
Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Regeneron Pharmaceuticals Inc., profitability ratios (quarterly data)
Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Regeneron Pharmaceuticals Inc.’s gross profit margin ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Regeneron Pharmaceuticals Inc.’s operating profit margin ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Regeneron Pharmaceuticals Inc.’s net profit margin ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Regeneron Pharmaceuticals Inc.’s ROE deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level. |
| ROA | A profitability ratio calculated as net income divided by total assets. | Regeneron Pharmaceuticals Inc.’s ROA improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Gross Profit Margin
Regeneron Pharmaceuticals Inc., gross profit margin calculation (quarterly data)
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
| Gross profit | 1,676,500 | 1,610,900 | 1,945,600 | 1,821,800 | 1,781,200 | 1,532,600 | 1,810,625 | 1,553,127 | 1,516,361 | 1,396,587 | 1,476,707 | 1,396,441 | 1,367,195 | 1,234,823 | 1,152,146 | 1,175,894 | 1,143,596 | 1,089,097 | 987,246 | 1,028,339 | 909,777 | 785,657 | |||||||
| Revenues | 1,952,000 | 1,828,200 | 2,169,500 | 2,048,400 | 1,933,700 | 1,711,800 | 1,927,797 | 1,663,496 | 1,608,022 | 1,511,485 | 1,582,447 | 1,500,673 | 1,470,116 | 1,318,991 | 1,226,827 | 1,220,122 | 1,212,629 | 1,200,849 | 1,098,077 | 1,137,422 | 998,617 | 869,612 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| Gross profit margin1 | 88.21% | 89.72% | 90.05% | 91.14% | 92.27% | 92.79% | 93.53% | 93.36% | 93.28% | 92.95% | 93.24% | 93.37% | 94.16% | 94.53% | 93.83% | 92.90% | 91.38% | 90.52% | 90.43% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 50.97% | 52.13% | 52.46% | 52.39% | 52.17% | 51.57% | 51.32% | 50.57% | 50.38% | 49.39% | 47.75% | 48.59% | 49.21% | 51.32% | 54.09% | 54.17% | 53.99% | 53.93% | 54.19% | — | — | — | |||||||
| AbbVie Inc. | 73.56% | 77.43% | 77.64% | 77.32% | 77.41% | 77.07% | 76.44% | 75.22% | 74.93% | 75.18% | 75.05% | 76.85% | 76.78% | 76.81% | 77.25% | 77.21% | 78.12% | 79.28% | 80.31% | — | — | — | |||||||
| Amgen Inc. | 77.15% | 78.90% | 80.38% | 81.19% | 81.23% | 81.26% | 81.80% | 81.61% | 81.78% | 81.69% | 81.33% | 81.37% | 81.26% | 81.05% | 80.99% | 80.68% | 80.64% | 80.23% | 79.82% | — | — | — | |||||||
| Biogen Inc. | 87.97% | 87.47% | 86.40% | 85.97% | 85.59% | 85.72% | 86.50% | 86.12% | 86.43% | 86.57% | 86.72% | 87.34% | 86.80% | 86.56% | 87.08% | 87.46% | 88.21% | 88.65% | 88.48% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 69.59% | 68.08% | 69.10% | 69.65% | 69.93% | 70.77% | 70.98% | 70.37% | 70.12% | 69.62% | 70.80% | 71.92% | 72.78% | 74.19% | 74.54% | 75.56% | 75.55% | 75.67% | 76.39% | — | — | — | |||||||
| Eli Lilly & Co. | 78.67% | 79.22% | 78.85% | 77.78% | 76.67% | 74.96% | 73.81% | 73.39% | 72.92% | 72.95% | 73.46% | 73.69% | 73.89% | 73.78% | 73.35% | 73.23% | 73.72% | 74.39% | 74.76% | — | — | — | |||||||
| Gilead Sciences Inc. | 78.25% | 79.06% | 78.86% | 79.27% | 78.98% | 78.02% | 77.61% | 79.21% | 80.31% | 81.82% | 82.97% | 84.51% | 84.71% | 85.95% | 85.77% | 86.36% | 86.91% | 86.69% | 87.54% | — | — | — | |||||||
| Illumina Inc. | 70.34% | 70.36% | 69.63% | 69.24% | 68.84% | 69.06% | 69.01% | 69.44% | 68.85% | 67.98% | 66.35% | 65.68% | 66.26% | 67.53% | 69.48% | 69.91% | 69.96% | 69.74% | 69.80% | — | — | — | |||||||
| Johnson & Johnson | 65.66% | 66.15% | 66.42% | 66.49% | 66.67% | 66.80% | 66.79% | 66.36% | 65.69% | 66.22% | 66.84% | 68.20% | 69.35% | 69.88% | 69.84% | 69.52% | 69.58% | 69.25% | 69.27% | — | — | — | |||||||
| Merck & Co. Inc. | 70.06% | 70.11% | 69.87% | 70.13% | 69.89% | 68.94% | 68.06% | 67.35% | 67.81% | 68.22% | 68.16% | 68.09% | 67.92% | 66.61% | 65.10% | 63.89% | 62.58% | 62.07% | 62.19% | — | — | — | |||||||
| Pfizer Inc. | 79.94% | 79.94% | 80.25% | 79.85% | 79.91% | 79.36% | 79.03% | 78.58% | 78.24% | 78.48% | 78.61% | 78.66% | 78.15% | 77.28% | 76.66% | 76.48% | 77.71% | 79.09% | 80.25% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 87.71% | 87.24% | 86.84% | 86.60% | 86.56% | 86.74% | 86.56% | 86.88% | 87.31% | 87.59% | 88.95% | 89.04% | 89.08% | 89.76% | 87.64% | 87.16% | 87.72% | 87.39% | 87.94% | — | — | — | |||||||
| Zoetis Inc. | 69.73% | 69.51% | 68.18% | 67.38% | 66.92% | 66.49% | 67.19% | 68.12% | 68.04% | 67.31% | 66.55% | 65.14% | 64.91% | 65.30% | 65.92% | 65.32% | 64.90% | 64.08% | 63.53% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).
1 Q2 2020 Calculation
Gross profit margin = 100
× (Gross profitQ2 2020
+ Gross profitQ1 2020
+ Gross profitQ4 2019
+ Gross profitQ3 2019)
÷ (RevenuesQ2 2020
+ RevenuesQ1 2020
+ RevenuesQ4 2019
+ RevenuesQ3 2019)
= 100 × (1,676,500 + 1,610,900 + 1,945,600 + 1,821,800)
÷ (1,952,000 + 1,828,200 + 2,169,500 + 2,048,400)
= 88.21%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Regeneron Pharmaceuticals Inc.’s gross profit margin ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Operating Profit Margin
Regeneron Pharmaceuticals Inc., operating profit margin calculation (quarterly data)
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
| Income from operations | 656,400 | 700,100 | 675,700 | 738,500 | 315,600 | 480,000 | 718,058 | 626,923 | 622,188 | 567,231 | 538,811 | 559,926 | 550,312 | 430,542 | 347,003 | 362,802 | 291,628 | 329,308 | 231,082 | 392,422 | 344,859 | 283,553 | |||||||
| Revenues | 1,952,000 | 1,828,200 | 2,169,500 | 2,048,400 | 1,933,700 | 1,711,800 | 1,927,797 | 1,663,496 | 1,608,022 | 1,511,485 | 1,582,447 | 1,500,673 | 1,470,116 | 1,318,991 | 1,226,827 | 1,220,122 | 1,212,629 | 1,200,849 | 1,098,077 | 1,137,422 | 998,617 | 869,612 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| Operating profit margin1 | 34.64% | 30.45% | 28.10% | 29.55% | 29.58% | 35.41% | 37.77% | 37.00% | 36.89% | 36.54% | 35.41% | 34.22% | 32.29% | 28.76% | 27.38% | 25.67% | 26.77% | 29.26% | 30.51% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 12.78% | 14.18% | 14.21% | 13.74% | 13.27% | 12.31% | 11.94% | 10.45% | 10.11% | 8.92% | 6.30% | 7.89% | 8.77% | 11.03% | 15.27% | 14.74% | 13.95% | 13.64% | 14.05% | — | — | — | |||||||
| AbbVie Inc. | 30.17% | 39.86% | 39.03% | 20.04% | 21.85% | 19.88% | 19.49% | 32.99% | 32.84% | 34.03% | 33.99% | 37.24% | 36.74% | 36.33% | 36.60% | 36.21% | 35.00% | 34.18% | 32.97% | — | — | — | |||||||
| Amgen Inc. | 39.76% | 41.89% | 43.57% | 44.83% | 44.05% | 44.53% | 45.55% | 45.82% | 46.46% | 46.07% | 45.76% | 46.66% | 46.93% | 45.68% | 44.74% | 43.33% | 42.46% | 41.53% | 40.44% | — | — | — | |||||||
| Biogen Inc. | 50.93% | 51.03% | 48.98% | 47.13% | 46.90% | 42.40% | 43.77% | 44.67% | 45.58% | 46.49% | 43.54% | 40.25% | 38.72% | 41.59% | 44.99% | 47.59% | 47.86% | 47.11% | 45.44% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 11.67% | 16.30% | 22.62% | 28.64% | 28.60% | 23.44% | 22.69% | 18.64% | 15.93% | 17.50% | 17.39% | 19.71% | 21.73% | 24.06% | 23.83% | 19.21% | 16.34% | 11.09% | 11.41% | — | — | — | |||||||
| Eli Lilly & Co. | 24.48% | 25.64% | 22.29% | 20.00% | 19.48% | 12.50% | 15.15% | 12.34% | 9.11% | 14.88% | 9.38% | 12.43% | 14.23% | 12.92% | 16.30% | 14.31% | 14.56% | 14.27% | 13.47% | — | — | — | |||||||
| Gilead Sciences Inc. | -4.40% | 19.89% | 19.38% | 19.71% | 38.44% | 37.87% | 37.83% | 42.81% | 46.25% | 51.51% | 55.04% | 58.72% | 58.71% | 58.46% | 58.87% | 61.67% | 63.83% | 66.22% | 69.03% | — | — | — | |||||||
| Illumina Inc. | 25.69% | 27.28% | 27.80% | 26.42% | 24.88% | 25.58% | 26.49% | 28.25% | 27.58% | 26.29% | 22.02% | 20.01% | 20.06% | 21.35% | 24.48% | 24.80% | 24.55% | 24.77% | 27.61% | — | — | — | |||||||
| Johnson & Johnson | 24.64% | 25.62% | 24.15% | 24.15% | 22.63% | 22.69% | 24.27% | 22.59% | 23.05% | 23.63% | 24.07% | 27.02% | 28.55% | 28.83% | 28.72% | 26.37% | 25.66% | 25.00% | 25.05% | — | — | — | |||||||
| Merck & Co. Inc. | 25.40% | 25.49% | 24.77% | 25.56% | 26.73% | 24.38% | 19.62% | 17.84% | 12.28% | 13.57% | 16.28% | 9.92% | 16.85% | 14.45% | 13.51% | 19.60% | 18.10% | 18.19% | 17.54% | — | — | — | |||||||
| Pfizer Inc. | 23.75% | 25.38% | 25.46% | 26.30% | 27.50% | 26.86% | 26.10% | 26.18% | 26.00% | 25.86% | 25.92% | 24.69% | 23.57% | 22.94% | 22.73% | 22.96% | 24.02% | 24.86% | 24.20% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 38.67% | 34.05% | 28.77% | 21.38% | 25.48% | 23.98% | 20.84% | 22.38% | 3.87% | -0.77% | 4.95% | 1.62% | 16.16% | 14.62% | 0.58% | -5.02% | -8.65% | -23.94% | -45.23% | — | — | — | |||||||
| Zoetis Inc. | 33.36% | 32.72% | 31.42% | 31.01% | 29.80% | 30.05% | 31.12% | 33.00% | 33.86% | 33.02% | 32.15% | 29.43% | 28.34% | 28.55% | 28.48% | 26.22% | 24.91% | 17.35% | 15.74% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).
1 Q2 2020 Calculation
Operating profit margin = 100
× (Income from operationsQ2 2020
+ Income from operationsQ1 2020
+ Income from operationsQ4 2019
+ Income from operationsQ3 2019)
÷ (RevenuesQ2 2020
+ RevenuesQ1 2020
+ RevenuesQ4 2019
+ RevenuesQ3 2019)
= 100 × (656,400 + 700,100 + 675,700 + 738,500)
÷ (1,952,000 + 1,828,200 + 2,169,500 + 2,048,400)
= 34.64%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Regeneron Pharmaceuticals Inc.’s operating profit margin ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Net Profit Margin
Regeneron Pharmaceuticals Inc., net profit margin calculation (quarterly data)
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
| Net income | 897,300 | 624,600 | 792,000 | 669,600 | 193,100 | 461,100 | 820,353 | 594,655 | 551,412 | 477,980 | 173,519 | 388,317 | 387,744 | 248,931 | 253,115 | 264,804 | 196,218 | 181,385 | 154,994 | 210,398 | 194,643 | 76,021 | |||||||
| Revenues | 1,952,000 | 1,828,200 | 2,169,500 | 2,048,400 | 1,933,700 | 1,711,800 | 1,927,797 | 1,663,496 | 1,608,022 | 1,511,485 | 1,582,447 | 1,500,673 | 1,470,116 | 1,318,991 | 1,226,827 | 1,220,122 | 1,212,629 | 1,200,849 | 1,098,077 | 1,137,422 | 998,617 | 869,612 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| Net profit margin1 | 37.30% | 28.56% | 26.91% | 28.13% | 28.59% | 35.12% | 36.42% | 28.24% | 25.65% | 23.54% | 20.41% | 23.17% | 22.05% | 19.34% | 18.42% | 16.85% | 15.98% | 16.72% | 15.50% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 9.89% | 11.15% | 11.56% | 10.50% | 9.36% | 8.53% | 7.74% | 2.91% | 3.13% | 1.67% | 1.74% | 8.37% | 4.96% | 6.74% | 6.71% | 6.61% | 11.08% | 12.00% | 21.68% | — | — | — | |||||||
| AbbVie Inc. | 19.20% | 24.77% | 23.69% | 9.90% | 12.62% | 16.42% | 17.36% | 23.50% | 20.84% | 21.55% | 18.82% | 24.38% | 24.77% | 24.07% | 23.22% | 24.08% | 23.11% | 23.03% | 22.50% | — | — | — | |||||||
| Amgen Inc. | 31.53% | 33.64% | 35.32% | 36.14% | 35.57% | 35.93% | 37.25% | 9.96% | 10.72% | 10.11% | 9.08% | 37.36% | 37.24% | 36.12% | 35.27% | 35.19% | 34.48% | 33.86% | 33.13% | — | — | — | |||||||
| Biogen Inc. | 40.91% | 40.76% | 40.96% | 37.91% | 37.62% | 33.79% | 32.93% | 24.08% | 23.06% | 23.54% | 20.69% | 29.44% | 28.10% | 30.17% | 32.34% | 34.03% | 33.97% | 33.79% | 32.95% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -1.61% | 3.08% | 13.15% | 23.39% | 26.00% | 22.09% | 21.81% | 6.50% | 1.74% | 4.37% | 4.85% | 20.56% | 22.66% | 24.22% | 22.94% | 18.22% | 16.29% | 9.31% | 9.45% | — | — | — | |||||||
| Eli Lilly & Co. | 24.48% | 23.97% | 37.27% | 35.10% | 33.76% | 26.12% | 13.16% | 1.85% | -0.60% | 4.82% | -0.89% | 9.90% | 11.12% | 10.13% | 12.90% | 11.73% | 11.97% | 11.49% | 12.07% | — | — | — | |||||||
| Gilead Sciences Inc. | -1.18% | 22.17% | 24.35% | 12.24% | 27.14% | 26.93% | 25.16% | 7.27% | 9.69% | 14.26% | 18.03% | 42.90% | 43.55% | 44.11% | 45.07% | 48.40% | 51.16% | 53.48% | 56.32% | — | — | — | |||||||
| Illumina Inc. | 20.68% | 26.49% | 28.28% | 28.13% | 27.55% | 25.05% | 24.78% | 21.09% | 20.88% | 19.31% | 26.38% | 30.14% | 30.07% | 30.52% | 19.29% | 18.70% | 18.70% | 18.40% | 20.79% | — | — | — | |||||||
| Johnson & Johnson | 18.86% | 20.75% | 18.42% | 17.32% | 20.08% | 17.99% | 18.75% | 1.89% | 1.70% | 1.58% | 1.70% | 21.28% | 22.52% | 22.87% | 23.01% | 22.27% | 21.20% | 22.15% | 21.99% | — | — | — | |||||||
| Merck & Co. Inc. | 22.20% | 21.10% | 21.01% | 20.26% | 21.10% | 19.50% | 14.71% | 8.02% | 3.25% | 3.88% | 5.97% | 7.15% | 12.71% | 10.88% | 9.85% | 13.76% | 13.01% | 11.72% | 11.25% | — | — | — | |||||||
| Pfizer Inc. | 28.80% | 31.17% | 31.45% | 30.57% | 23.58% | 21.31% | 20.79% | 44.63% | 42.35% | 41.29% | 40.55% | 18.69% | 15.90% | 13.88% | 13.66% | 11.77% | 13.47% | 14.95% | 14.25% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 38.51% | 31.35% | 28.27% | 59.23% | 64.13% | 66.01% | 68.80% | 22.87% | 15.84% | 9.36% | 10.59% | 8.53% | 12.19% | 8.78% | -6.58% | -13.17% | -17.66% | -30.91% | -53.89% | — | — | — | |||||||
| Zoetis Inc. | 25.50% | 25.41% | 23.96% | 23.76% | 22.74% | 23.47% | 24.52% | 20.35% | 19.95% | 17.97% | 16.28% | 18.29% | 17.50% | 17.25% | 16.80% | 14.10% | 13.15% | 7.83% | 7.11% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).
1 Q2 2020 Calculation
Net profit margin = 100
× (Net incomeQ2 2020
+ Net incomeQ1 2020
+ Net incomeQ4 2019
+ Net incomeQ3 2019)
÷ (RevenuesQ2 2020
+ RevenuesQ1 2020
+ RevenuesQ4 2019
+ RevenuesQ3 2019)
= 100 × (897,300 + 624,600 + 792,000 + 669,600)
÷ (1,952,000 + 1,828,200 + 2,169,500 + 2,048,400)
= 37.30%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Regeneron Pharmaceuticals Inc.’s net profit margin ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Return on Equity (ROE)
Regeneron Pharmaceuticals Inc., ROE calculation (quarterly data)
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
| Net income | 897,300 | 624,600 | 792,000 | 669,600 | 193,100 | 461,100 | 820,353 | 594,655 | 551,412 | 477,980 | 173,519 | 388,317 | 387,744 | 248,931 | 253,115 | 264,804 | 196,218 | 181,385 | 154,994 | 210,398 | 194,643 | 76,021 | |||||||
| Stockholders’ equity | 9,057,400 | 12,133,000 | 11,089,700 | 10,504,400 | 9,755,900 | 9,444,700 | 8,757,300 | 7,868,300 | 7,186,426 | 6,567,644 | 6,144,078 | 6,051,593 | 5,520,738 | 4,866,021 | 4,449,245 | 4,491,247 | 4,076,506 | 3,765,082 | 3,654,837 | 3,296,867 | 3,338,458 | 2,971,430 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| ROE1 | 32.94% | 18.79% | 19.08% | 20.41% | 21.21% | 25.70% | 27.91% | 22.85% | 22.14% | 21.74% | 19.51% | 21.12% | 20.91% | 19.79% | 20.13% | 17.75% | 18.23% | 19.69% | 17.40% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 10.17% | 11.84% | 11.86% | 10.35% | 9.14% | 8.48% | 7.76% | 2.89% | 3.03% | 1.52% | 1.54% | 6.57% | 3.71% | 4.79% | 6.82% | 6.59% | 11.02% | 11.81% | 20.85% | — | — | — | |||||||
| AbbVie Inc. | 47.30% | — | — | — | — | — | — | — | — | 179.59% | 104.16% | 99.42% | 110.08% | 126.25% | 128.41% | 93.97% | 101.42% | 117.94% | 130.39% | — | — | — | |||||||
| Amgen Inc. | 68.48% | 80.92% | 81.07% | 73.83% | 73.73% | 74.55% | 67.15% | 15.35% | 15.86% | 14.21% | 7.84% | 25.37% | 25.77% | 25.76% | 25.85% | 24.65% | 24.67% | 25.16% | 24.71% | — | — | — | |||||||
| Biogen Inc. | 52.41% | 46.85% | 44.13% | 38.55% | 40.87% | 33.74% | 33.98% | 23.15% | 24.21% | 21.09% | 20.13% | 27.10% | 28.42% | 30.31% | 30.50% | 32.06% | 33.48% | 35.78% | 37.84% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -1.15% | 1.91% | 6.66% | 32.04% | 38.65% | 33.80% | 35.07% | 10.50% | 3.05% | 7.18% | 8.58% | 28.61% | 31.20% | 33.55% | 27.55% | 21.56% | 19.24% | 10.94% | 10.97% | — | — | — | |||||||
| Eli Lilly & Co. | 137.26% | 179.72% | 319.09% | 234.97% | 282.08% | 252.24% | 32.88% | 3.44% | -1.24% | 7.74% | -1.76% | 14.94% | 17.35% | 15.58% | 19.54% | 15.68% | 16.85% | 15.45% | 16.53% | — | — | — | |||||||
| Gilead Sciences Inc. | -1.43% | 22.49% | 23.91% | 13.07% | 26.33% | 26.84% | 25.51% | 6.94% | 10.19% | 16.82% | 22.64% | 46.69% | 53.86% | 61.82% | 71.48% | 89.38% | 105.21% | 129.43% | 97.70% | — | — | — | |||||||
| Illumina Inc. | 15.19% | 20.32% | 21.72% | 21.92% | 21.65% | 21.36% | 21.98% | 19.53% | 19.90% | 18.85% | 26.41% | 27.38% | 27.54% | 29.01% | 21.06% | 19.79% | 21.05% | 20.82% | 24.97% | — | — | — | |||||||
| Johnson & Johnson | 24.11% | 28.01% | 25.42% | 24.31% | 26.87% | 24.90% | 25.60% | 2.39% | 2.18% | 1.97% | 2.16% | 21.39% | 22.71% | 23.46% | 23.49% | 21.91% | 20.73% | 21.40% | 21.66% | — | — | — | |||||||
| Merck & Co. Inc. | 37.91% | 38.72% | 37.99% | 34.70% | 33.88% | 30.50% | 23.30% | 10.32% | 4.12% | 4.69% | 6.97% | 7.44% | 12.89% | 10.91% | 9.78% | 12.55% | 11.84% | 10.53% | 9.94% | — | — | — | |||||||
| Pfizer Inc. | 22.02% | 24.28% | 25.77% | 24.91% | 21.24% | 19.52% | 17.59% | 33.40% | 32.31% | 29.72% | 29.88% | 16.14% | 14.26% | 12.49% | 12.12% | 9.90% | 11.22% | 12.09% | 10.75% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 27.67% | 23.38% | 19.34% | 40.81% | 43.70% | 45.63% | 47.28% | 22.27% | 15.46% | 9.41% | 12.99% | 10.93% | 15.55% | 11.82% | -9.69% | -21.41% | -28.03% | -41.73% | -59.19% | — | — | — | |||||||
| Zoetis Inc. | 54.23% | 58.52% | 55.39% | 54.56% | 57.03% | 59.91% | 65.35% | 54.96% | 56.60% | 49.90% | 48.81% | 47.11% | 51.20% | 53.14% | 55.21% | 43.47% | 47.09% | 32.45% | 31.74% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).
1 Q2 2020 Calculation
ROE = 100
× (Net incomeQ2 2020
+ Net incomeQ1 2020
+ Net incomeQ4 2019
+ Net incomeQ3 2019)
÷ Stockholders’ equity
= 100 × (897,300 + 624,600 + 792,000 + 669,600)
÷ 9,057,400 = 32.94%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Regeneron Pharmaceuticals Inc.’s ROE deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level. |
Return on Assets (ROA)
Regeneron Pharmaceuticals Inc., ROA calculation (quarterly data)
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
| Net income | 897,300 | 624,600 | 792,000 | 669,600 | 193,100 | 461,100 | 820,353 | 594,655 | 551,412 | 477,980 | 173,519 | 388,317 | 387,744 | 248,931 | 253,115 | 264,804 | 196,218 | 181,385 | 154,994 | 210,398 | 194,643 | 76,021 | |||||||
| Total assets | 14,428,700 | 15,757,500 | 14,805,200 | 13,939,300 | 13,173,600 | 12,854,800 | 11,734,500 | 10,805,613 | 9,951,980 | 9,372,696 | 8,764,286 | 8,701,215 | 8,106,373 | 7,817,365 | 6,973,466 | 6,828,019 | 6,204,906 | 5,904,460 | 5,609,132 | 5,182,915 | 4,526,970 | 4,198,573 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| ROA1 | 20.68% | 14.46% | 14.29% | 15.38% | 15.71% | 18.88% | 20.83% | 16.64% | 15.99% | 15.23% | 13.67% | 14.69% | 14.24% | 12.32% | 12.84% | 11.68% | 11.97% | 12.56% | 11.34% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 4.52% | 5.36% | 5.43% | 4.80% | 4.23% | 3.88% | 3.53% | 1.24% | 1.35% | 0.67% | 0.63% | 2.91% | 1.65% | 2.12% | 2.66% | 3.47% | 5.72% | 6.17% | 10.72% | — | — | — | |||||||
| AbbVie Inc. | 4.65% | 9.25% | 8.84% | 5.48% | 7.21% | 9.44% | 9.58% | 11.43% | 10.46% | 9.20% | 7.50% | 9.66% | 9.87% | 9.61% | 9.01% | 9.12% | 8.51% | 10.19% | 9.70% | — | — | — | |||||||
| Amgen Inc. | 11.23% | 12.45% | 13.13% | 13.55% | 13.40% | 12.62% | 12.64% | 3.27% | 3.49% | 3.12% | 2.48% | 10.18% | 10.27% | 10.14% | 9.95% | 9.71% | 9.85% | 9.61% | 9.69% | — | — | — | |||||||
| Biogen Inc. | 23.23% | 22.51% | 21.62% | 19.63% | 20.14% | 17.65% | 17.52% | 12.50% | 12.39% | 11.36% | 10.73% | 15.11% | 15.13% | 16.42% | 16.19% | 17.58% | 17.75% | 17.87% | 18.19% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -0.44% | 0.74% | 2.65% | 9.85% | 11.24% | 14.77% | 14.06% | 4.24% | 1.15% | 2.78% | 3.00% | 12.45% | 13.73% | 14.68% | 13.22% | 9.98% | 8.74% | 4.94% | 4.93% | — | — | — | |||||||
| Eli Lilly & Co. | 13.39% | 13.46% | 21.17% | 20.97% | 20.28% | 16.46% | 7.36% | 1.01% | -0.34% | 2.53% | -0.45% | 5.17% | 5.98% | 5.81% | 7.05% | 6.50% | 6.76% | 6.68% | 6.77% | — | — | — | |||||||
| Gilead Sciences Inc. | -0.46% | 8.31% | 8.74% | 4.55% | 9.42% | 9.38% | 8.57% | 2.47% | 3.38% | 5.30% | 6.58% | 17.94% | 20.27% | 21.90% | 23.70% | 26.63% | 32.71% | 36.30% | 34.93% | — | — | — | |||||||
| Illumina Inc. | 9.56% | 12.97% | 13.70% | 13.73% | 13.45% | 11.52% | 11.87% | 10.12% | 11.08% | 10.23% | 13.81% | 15.49% | 15.39% | 16.10% | 10.81% | 10.49% | 10.86% | 10.93% | 12.52% | — | — | — | |||||||
| Johnson & Johnson | 9.59% | 11.07% | 9.59% | 9.10% | 10.53% | 9.78% | 10.00% | 0.99% | 0.88% | 0.79% | 0.83% | 10.17% | 10.69% | 11.39% | 11.71% | 11.36% | 10.75% | 11.41% | 11.55% | — | — | — | |||||||
| Merck & Co. Inc. | 11.56% | 11.95% | 11.66% | 11.18% | 11.15% | 10.20% | 7.53% | 3.93% | 1.58% | 1.84% | 2.72% | 3.11% | 5.48% | 4.50% | 4.11% | 5.58% | 5.32% | 4.67% | 4.36% | — | — | — | |||||||
| Pfizer Inc. | 7.96% | 9.49% | 9.72% | 9.51% | 8.10% | 7.38% | 7.00% | 14.19% | 13.67% | 13.21% | 12.40% | 5.70% | 4.94% | 4.32% | 4.20% | 3.51% | 4.13% | 4.68% | 4.16% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 20.37% | 16.99% | 14.15% | 28.53% | 31.50% | 32.94% | 33.57% | 14.00% | 9.58% | 5.72% | 7.43% | 6.12% | 7.91% | 6.02% | -3.87% | -8.38% | -10.79% | -16.05% | -22.26% | — | — | — | |||||||
| Zoetis Inc. | 12.37% | 13.97% | 12.99% | 12.96% | 12.52% | 12.75% | 13.25% | 11.13% | 12.96% | 11.25% | 10.06% | 10.09% | 11.25% | 11.18% | 10.73% | 8.93% | 8.50% | 5.07% | 4.28% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).
1 Q2 2020 Calculation
ROA = 100
× (Net incomeQ2 2020
+ Net incomeQ1 2020
+ Net incomeQ4 2019
+ Net incomeQ3 2019)
÷ Total assets
= 100 × (897,300 + 624,600 + 792,000 + 669,600)
÷ 14,428,700 = 20.68%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Regeneron Pharmaceuticals Inc.’s ROA improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |